Milestone broadens partnership to develop novel ocular thera…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.

The RD Fund is changing how the world treats blinding retinal diseases.
Click here to download the January 2022 Outcomes & Outlook Report.

IN THE NEWS
OPGx-LCA5 is designed to address vision loss due to Leber co…
- Lead gene therapy asset, SPVN06, reported to be well-toler…
Amber Bio is developing a first-of-its-kind RNA writing plat…
Amber Bio’s proprietary platform leverages multi-kilobase RN…
Agreement provides ProQR with initial payment of €12.5M and …
New clinical site added and early safety signals observed in…
Dr. Léveillard helped discover and develop a gene-agnostic, …
Phase 1/2 SLO-RP trial completed target enrollment of 48 pat…
- First oral presentation on SPVN20 in a major scientific and…
ATSN-201 leverages AAV capsid that spreads laterally beyond …
Paris, April 27, 2023 – SparingVision (“the Company”), a cli…